Psilocybin for Obsessive-Compulsive Disorder
Study Summary
This trial will study the effects of psilocybin on obsessive-compulsive disorder and assess psychological mechanisms that may explain any therapeutic effects.
- Obsessive-Compulsive Disorder
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What potential risks accompany the utilization of Psilocybin?
"Power has assessed the safety of Psilocybin to be a 1, as this is just a Phase 1 trial and there has been limited evidence supporting its efficacy and safety."
Is this trial suitable for geriatric individuals?
"Qualified participants of this clinical trial must be between 18-65 years old, with 23 trials for those under the age limit and 67 trials available to people over 65."
Are there still opportunities for participants to take part in this experiment?
"Clinicaltrials.gov has registered this trial as inactive; it was initially posted on February 1st, 2023 and its most recent edit took place on November 21st 2022. Despite the fact that this clinical study is not accepting participants presently, there are 114 other research initiatives which currently require volunteers."
Under what conditions can individuals participate in this research?
"This clinical trial is seeking 30 participants between 18 and 65 years old who have been diagnosed with obsessive-compulsive disorder. To apply, candidates must meet several criteria: they must accept all study procedures, possess a primary DSM-5 diagnosis of OCD (with Y-BOCS-II score greater than 26), be unresponsive to standard care treatment for OCD, provide an adult contact available in the event of emergency or transportation purposes, demonstrate fluency in English language, grant permission for investigators to communicate directly about their medication/psychotherapy histories; consent to lifestyle modifications related to the test intervention as well as refrain from taking any psychiatric medications 4"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- Connecticut Mental Health Center: < 48 hours
Average response time
- < 2 Days